SCHEMBL4339516

SCHEMBL4339516

CN(C)Cc1nc(CO)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.44
ACHE P22303 1/20 0.41
EPHB4 P54760 1/20 0.33
NUDT1 P36639 1/20 0.32
ENPP2 Q13822 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
MMP13 P45452 1/20 0.31
BCHE P06276 1/20 0.31
SRC P12931 1/20 0.31
CDK2 P24941 1/20 0.31
ZAP70 P43403 1/20 0.31
SYK P43405 1/20 0.31
SLC6A4 P31645 1/20 0.30
F2RL3 Q96RI0 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8600010 0.98 CNR2 (0.43) CNR2ACHEEPHB4NUDT1ENPP2
SCHEMBL18157890 0.86 CNR2 (0.44) CNR2ACHEEPHB4ENPP2MEN1
SCHEMBL10958555 0.85 CNR2 (0.38) CNR2ACHEEPHB4ENPP2MEN1
SCHEMBL10425952 0.84 NUDT1 (0.33) CNR2ACHENUDT1MEN1KMT2A
SCHEMBL10785829 0.81 HDAC1 (0.33) CNR2NUDT1HDAC1HDAC6
SCHEMBL8027980 0.81 ALDH1A1 (0.41) CNR2ACHEEPHB4KMT2AALDH1A1
SCHEMBL9839838 0.81 CNR2 (0.41) CNR2ACHEEPHB4F2RL3
SCHEMBL9839846 0.81 CNR2 (0.41) CNR2ACHEEPHB4F2RL3
SCHEMBL8015431 0.81 CNR2 (0.41) CNR2ACHEEPHB4F2RL3
Hydrochloric Acid SCHEMBL907030 0.79 ALDH1A1 (0.43) CNR2ACHEEPHB4KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119549176-A Preparation method of high-activity palladium-carbon catalyst and application of high-activity palladium-carbon catalyst in preparation of monosilane 成都至诚大公光电科技有限公司 2025-03-04 CN claimed
CN-1397553-A Process for preparing Nizatidine BIAN LUSHENG (CN) 2003-02-19 CN claimed
US-4904792-A N-thiazolymethylthioalkyl-N'-alkylamidines and related compounds ELI LILLY AND COMPANY (US) 1990-02-27 US claimed
US-4348336-A Process for the isolation of 1-naphthylamine-4,6- and 1-naphthylamine-4,7-disulphonic acid BAYER AKTIENGESELLSCHAFT (DE) 1982-09-07 US claimed
CN-119549176-A Preparation method of high-activity palladium-carbon catalyst and application of high-activity palladium-carbon catalyst in preparation of monosilane 成都至诚大公光电科技有限公司 2025-03-04 CN disclosed
CN-119549176-A Preparation method of high-activity palladium-carbon catalyst and application of high-activity palladium-carbon catalyst in preparation of monosilane 成都至诚大公光电科技有限公司 2025-03-04 CN disclosed
CN-217888010-U Equipment for synthesizing intermediate of nizatidine product 无棣融川医药化工科技有限公司 2022-11-25 CN disclosed
CN-217868685-U Production system of nizatidine product intermediate 无棣融川医药化工科技有限公司 2022-11-22 CN disclosed
CN-109485567-A A kind of clean method for preparing and its intermediate of 4- hydroxymethylthiazole 上海博璞诺科技发展有限公司 2019-03-19 CN disclosed
US-20090275622-A1 NIZATIDINE FORMULATIONS DR. REDDY'S LABORATORIES LIMITED (IN) 2009-11-05 US disclosed
EP-0900799-B1 Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones PFIZER PROD INC (US) 2005-06-08 EP disclosed
EP-0968194-B1 ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2004-05-26 EP disclosed
US-4394508-A ANTIULCER AND ANTISECRETORY AGENTS; HISTAMINE ANTAGONIST BRISTOL-MYERS COMPANY (US) 1983-07-19 US disclosed
EP-0083186-A2 Thiazole derivatives as H2-receptor antagonists ELI LILLY AND COMPANY (US) 1983-07-06 EP disclosed
US-4382090-A N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds ELI LILLY AND COMPANY (US) 1983-05-03 US disclosed
US-4380639-A ANTIULCER AND ANTISECRETORY AGENTS BRISTOL-MYERS COMPANY (US) 1983-04-19 US disclosed
US-4380638-A ANTIULCER AND ANTISECRETORY AGENTS; DERIVATIVES OF 3-AMINO-4-HET-A BRISTOL-MYERS COMPANY (US) 1983-04-19 US disclosed
US-4375547-A ANTIHISTAMINES, 'I RECEPTOR ANTAGONISTS, ANTISECRETORY AGENTS ELI LILLY AND COMPANY (US) 1983-03-01 US disclosed
US-4374248-A ANTIHISTAMINES, ANTIULCER BRISTOL-MYERS COMPANY (US) 1983-02-15 US disclosed
EP-0049618-A1 Improvements in or relating to 2,4-disubstituted thiazole derivatives ELI LILLY AND COMPANY (US) 1982-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275622-A1 NIZATIDINE FORMULATIONS SLC30A5, SLC39A11, NNMT CNR2 4039/4885ACHE 1618/4885EPHB4 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.